关键词: 糖尿病, 2型；达格列净；利格列汀；代谢指标；PR间期；治疗结果

Abstract: Background　Metabolic disorder is an important risk factor for cardiovascular complications associated with type 2 diabetes mellitus（T2DM），a major cause of death in T2DM patients，and PR interval extension is a key marker of subclinical phase of development of such diseases.Objective　To investigate the effects of dapagliflozin and linagliptin on metabolic indices and PR interval among T2DM patients.Methods　80 T2DM inpatients recruited from Department of Endocrinology，the Second Affiliated Hospital of Zhengzhou University during October 2018 to June 2019 were equally randomized into dapagliflozin group and linagliptin group，receiving oral administration of dapagliflozin 10 mg/d，and linagliptin 5 mg/d，respectively，besides maintaining previous antihypertensive or lipid-lowering therapies during a consecutive 24-week treatment.Body weight，blood pressure，HbA1c，fasting plasma glucose （FPG），total cholesterol （TC），triglyceride （TG），high-density lipoprotein cholesterol （HDL-C），low-density lipoprotein cholesterol （LDL-C），serum uric acid （SUA） and PR interval before and after treatment，as well as treatment-emergent adverse reactions were collected..Results　Finally，70 cases（each group had 35 cases） completed the study.There were no significant intergroup differences in mean post-treatment body weight，systolic blood pressure，diastolic blood pressure，FPG，TC，TG，HDL-C，LDL-C，SUA and PR interval（P>0.05），but mean post-treatment HbA1c level was much lower in dapagliflozin group （P<0.05）.Dapagliflozin group showed significantly decreased body weight，HbA1c，FPG，TG and SUA，and much reduced PR interval after treatment （P<0.05），but showed insignificant changes in systolic blood pressure，diastolic blood pressure，TC，HDL-C and LDL-C （P>0.05）.Linagliptin group demonstrated significantly decreased HbA1c and FPG after treatment （P<0.05），but demonstrated insignificant changes in body weight，systolic blood pressure，diastolic blood pressure，TC，TG，HDL-C and LDL-C，SUA and PR interval （P>0.05）.No serious adverse reactions or acute cardiovascular and cerebrovascular events occurred during treatment for both groups.Conclusion　Both dapagliflozin and linagliptin could reduce the blood glucose level，but dapagliflozin had better effects on reducing the body weight，TG and SUA，and shortening the PR interval.

Key words: Diabetes mellitus, type 2；Dapagliflozin；Linagliptin；Metabolic index；PR interval；Treatment outcome